Skip main navigation

Military Health System

Hurricane Milton & Hurricane Helene

Emergency procedures are in place in multiple states due to Hurricane Milton & Hurricane Helene. >>Learn More

Military, Industry Collaboration Critical to Success of Vaccine Research, Development

Image of Military, Industry Collaboration Critical to Success of Vaccine Research, Development. Cheryl Ewing and Julie Norton, research scientists with Naval Medical Research Center’s Deployment Associated Infections Division, inoculate Campylobacter jejuni bacteria as part of the laboratory’s vaccine research process. The Department of Defense and Defense Health Agency often work with outside entities to research and develop vaccines for a number of diseases. More recently, concerns about mosquito-borne infections have increased worldwide, such as the chikungunya virus. The U.S. military uses all available vaccines to prevent mosquito-borne infections, like chikungunya, Japanese encephalitis, and yellow fever, according to Centers for Disease Control and Prevention guidelines. (Photo by Michael Wilson/Naval Medical Research Command)

Throughout history, vaccines have been successful in mitigating the effects of diseases like smallpox, polio, measles, and tetanus around the world—and vaccines continue to be the best defense against common, sometimes deadly infections, according to the Centers for Disease Control and Prevention.

The COVID-19 pandemic further demonstrated the importance of vaccine research and development, which continues to be a top priority for civilian and military health officials. Within the Department of Defense, several organizations work in tandem to advance vaccine development to protect service members and their families.

Combating Invisible Enemies

From a military standpoint, infectious diseases pose a significant risk to the operational effectiveness of the warfighter. With service members deployed in every part of the world, one way to maintain effectiveness is to develop vaccines against prioritized threats to the health of the joint force.

The Military Infectious Diseases Research Program focuses on vaccines to prevent or mitigate these threats. Part of the Defense Health Agency’s Research and Development organization at Fort Detrick, Maryland, the program’s mission is to plan, coordinate, and oversee requirements-driven medical solutions to maximize warfighter readiness and performance.

“Vaccines and other preventive medical countermeasures keep service members in the fight and minimize lost duty days,” said U.S. Army Lt. Col. Katie Carr, military deputy director for MIDRP. “We collaborate with government, academia, and industry partners to advance the research, development, and production of vaccines for diseases that occur in parts of the world where U.S. troops are deployed.”

The U.S. military has been a major innovator in vaccine development and DOD collaborations have led to the successful development of multiple vaccines to benefit military and public health, according to Carr. In fact, the Walter Reed Army Institute of Research has its roots in the Yellow Fever Commission, established by U.S. Army Maj. Walter Reed after the Spanish-American War, which pioneered a successful vaccine against the disease still in use today.

Other vaccines developed by the U.S. Army include those to prevent adenovirus, influenza, rubella, meningitis, and hepatitis. In 2019, decades of research performed at the U.S. Army Medical Research Institute of Infectious Diseases, another DHA Research and Development laboratory, supported the Food and Drug Administration’s approval of vaccines to protect against Ebola and mpox viruses.

Monitoring Emerging Threats

More recently, concerns about mosquito-borne infections have increased worldwide. One mosquito-borne pathogen, chikungunya virus, has been detected in widening geographic areas, likely due to climate change. Chikungunya may cause fever and joint pain, according to DHA-Public Health. It has been found in areas in Africa, the Americas, Asia, and Europe, as well as islands in the Caribbean, and the Indian and Pacific Oceans.

Only a few cases of chikungunya infection have ever been diagnosed in service members. Nonetheless, having a vaccine available in case of growing chikungunya threats is valuable, said Dr. Margaret Ryan, medical director for immunization health at DHA.

In 2023, a chikungunya virus vaccine received FDA approval using the accelerated approval pathway, which allows the agency to approve certain products based on evidence of a product’s effectiveness that is reasonably likely to predict clinical benefit. The vaccine is recommended by CDC for travelers going to locations with active chikungunya outbreaks, and the vaccine may be considered in other special situations.

Ryan noted the military uses all available vaccines to prevent mosquito-borne infections like chikungunya, Japanese encephalitis, and yellow fever, in accordance with CDC guidelines. Using other countermeasures to prevent mosquito bites remains extremely important, according to Ryan, because there are many mosquito-borne infections that are not yet vaccine-preventable.

Overseeing Vaccine Development

At DHA Research and Development, experts within the Warfighter Protection and Acute Care Project Management Office continually leverage innovations across the whole of government, industry, and academia, according to Dr. Kendra Lawrence, who heads the WPAC PMO.

“Vaccine development is extremely expensive, and partnering with industry helps DOD maximize return on investment,” Lawrence explained. “At U.S. Army Medical Material Development Activity, we work to identify the most promising solutions for preventing and treating infectious diseases of military importance. This reduces redundancy and maximizes efficiencies with research investments to ensure that commercial solutions can meet military needs.”

U.S. Army Col. Matthew Clark of the DOD’s Joint Program Manager for Chemical, Biological, Radiological, and Nuclear Medical, explains vaccines with a viable commercial market are the essential “engine” for preparedness for both biodefense and global health. A viable market, regardless of size, helps ensure the availability of a stable and steady supply for the warfighter and the public when needed.

“Partnerships are the flywheel that keeps the engine operating in top form. They can be as simple as information sharing or collaborations through cooperative research and development agreements to test commercial products within military-specific use cases,” said Clark. “As products mature, competitive prototyping and down-selection of potential solutions can result in more substantial investments from the DOD to advance products for FDA approval.”

The Office of Regulated Activities also plays a key role in helping to develop medical products for military use, according to U.S. Army Lt. Col. Victor Zottig, ORA’s deputy director. The office provides regulatory support to assist in advancing potential vaccines through the FDA pathway to final approval, post-marketing requirements, and fielding.

“ORA supports vaccine developers at both the USAMMDA and the Joint Project Manager CBRN Medical with regulatory consultation support,” said Zottig. “As a member of an integrated product team, we evaluate the commercial development partner’s regulatory strategy, as well as assisting with document preparation and facilitating their interactions with the FDA.”

Supporting Warfighter Readiness

To ensure DOD continues to focus on the right targets, Carr said a panel of stakeholders and infectious disease experts convene every three to four years to prioritize infectious disease threats to the military. “This panel helps to identify the diseases of top concern to the DOD and map out a plan for developing medical solutions in coordination with government and industry partners,” explained Carr.

“Through these collaborations,” said Carr, “the DOD is ensuring medical countermeasures are available for our warfighters so they can be ready to support the mission—no matter where they may be deployed.”

You also may be interested in...

Article Around MHS
Sep 23, 2024

Military Infectious Diseases Research Program Focuses on Mitigating Disease Impacts in Large Scale Combat Operations

U.S. Army Staff Sgt. Matthew Pascual, a preventive medicine specialist with the Walter Reed Army Institute of Research Armed Forces Research Institute of Medical Sciences, processes samples for respiratory virus testing at Nimmarnkolayut Camp, Sa Kaeo, Thailand.

Prolonged care, degraded medical evacuation capability, and overstretched lines of communication during large-scale combat operations could increase the prevalence of disease-related injury and death among warfighters. These risks are what the U.S. Army Medical Research and Development Command's Military Infectious Diseases Research Program is working ...

Article Around MHS
Aug 27, 2024

WRAIR Researchers Discuss Vaccine Innovations at MHSRS

Dr. Essie Komla of the U.S. Army Medical Research and Development Command’s Walter Reed Army Institute of Research discusses research conducted by WRAIR in partnership with the Henry Jackson Foundation for the Advancement of Military Medicine to test the effectiveness of vaccines containing a new variant of the Army Liposome Formulation family of adjuvants in combating HIV, malaria, SARS-CoV-2, and Campylobacter.

Researchers from the U.S. Army Medical Research and Development Command’s Walter Reed Army Institute of Research shared their work to develop innovative approaches for preventing and treating infectious diseases of national security importance to the U.S. military, including HIV, malaria, and coronaviruses.

Article Around MHS
Aug 5, 2024

Naval Medical Research Unit INDO PACIFIC Monitors Infectious Disease for Public Health and Military Readiness

Military personnel at a meeting

The job of safeguarding the health of U.S. service members requires not just health care at the time of injury and sickness, but a vast suite of often unseen work to determine what illnesses service members might encounter, and to develop the countermeasures for an ever-evolving landscape of health risks that face the world.

Article Around MHS
Jun 18, 2024

U.S. Army Medical Research and Development Command’s Medical Technology Transfer Office Spotlights Inventions, Fosters Partnerships at Biotechnology Innovation Organization International

Military personnel at convention

Representatives from the U.S. Army Medical Research and Development Command’s Medical Technology Transfer Office showcased new biomedical technologies available for commercial licensing and discussed collaborative opportunities with biotechnology industry representatives from around the world at the Biotechnology Innovation Organization’s annual ...

Article Around MHS
Apr 26, 2024

Researchers and Guard Physicians Set Their Sights on Mitigating the Impact of Blast Exposures

Military personnel and civilian researchers at a training at Fort McCoy

Red Arrow soldiers from the 1-120th Field Artillery Battalion and 1-105th Cavalry Squadron were visited by a team of civilian researchers and Wisconsin National Guard surgeons on April 9, 2024, during their training at Fort McCoy, Wisconsin, to discuss a study to measure blast exposure and evaluate associated effects among soldiers during routine ...

Article Around MHS
Apr 15, 2024

Food and Drug Administration Clears First AI Software for Hemorrhage Triage of Combat Casualties

APPRAISE-HRI machine

The U.S. Food and Drug Administration has cleared a first-of-its-kind artificial intelligence-powered smartphone application developed by the U.S. Army Medical Research and Development Command’s Biotechnology High Performance Computing Software Applications Institute that uses vital-sign data from trauma patients to assess their risk of hemorrhage.

Article Around MHS
Mar 14, 2024

Spray Foam Cast Developed by U.S. Army Medical Research and Development Command Adopted for Rehabilitation Exoskeleton

A prototype SUPORT Self Evacuation Splint is tested with a burdened patient load equivalent to 75 pounds of armor and a weighted pack.  (Photo by Paul Lagasse/Medical Research and Command)

A method for rapidly splinting injured limbs developed with the assistance of the U.S. Army Medical Research and Development Command is being incorporated into the next generation of exoskeletons. This new method aims to help injured warfighters regain their mobility and recover more quickly from their injuries.

Skip subpage navigation
Refine your search
Last Updated: August 08, 2024
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on X Follow us on YouTube Sign up on GovDelivery